Canada markets open in 5 hours 38 minutes
  • S&P/TSX

    19,290.98
    -19.76 (-0.10%)
     
  • S&P 500

    4,201.62
    +34.03 (+0.82%)
     
  • DOW

    34,548.53
    +318.19 (+0.93%)
     
  • CAD/USD

    0.8210
    -0.0017 (-0.21%)
     
  • CRUDE OIL

    64.90
    +0.19 (+0.29%)
     
  • BTC-CAD

    68,032.84
    -1,590.08 (-2.28%)
     
  • CMC Crypto 200

    1,458.50
    -12.92 (-0.88%)
     
  • GOLD FUTURES

    1,820.10
    +4.40 (+0.24%)
     
  • RUSSELL 2000

    2,241.42
    +0.05 (+0.00%)
     
  • 10-Yr Bond

    1.5610
    0.0000 (0.00%)
     
  • NASDAQ futures

    13,601.25
    +3.50 (+0.03%)
     
  • VOLATILITY

    18.43
    -0.72 (-3.76%)
     
  • FTSE

    7,098.19
    +22.02 (+0.31%)
     
  • NIKKEI 225

    29,357.82
    +26.45 (+0.09%)
     
  • CAD/EUR

    0.6796
    -0.0021 (-0.31%)
     

Stocks in play: Zenith Epigenetics Ltd.

  • Oops!
    Something went wrong.
    Please try again later.
Baystreet.ca
  • Oops!
    Something went wrong.
    Please try again later.

Announced today the dosing of first patient with a triple combination of ZEN-3694 + Merck’s immune check point inhibitor, KEYTRUDA, + Pfizer’s androgen receptor signaling inhibitor (ARSI), XTANDI, in a University of California, San Francisco (UCSF) investigator led metastatic castration resistant prostate cancer (mCRPC) Phase 2 clinical trial. ZEN-3694, the Company’s lead therapeutic compound, is being developed for epigenetic combination therapies in multiple oncology indications. Zenith Epigenetics Ltd. shares T.RVX are trading up $0.16 at $1.05.

Read: